PTCL
Haematology · 2016–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| romidepsin Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least one prior systemic therapy. | Mar 2026 | Recommended with restriction | 2 individuals Snowdome Foundation · Lymphoma Australia · Rare Cancers Australia |
| romidepsin Relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least first-line chemotherapy. | Dec 2017 | Deferred | 1 individuals |
| pralatrexate Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in patients who have undergone appropriate prior front-line curative intent chemotherapy. | Mar 2016 | Not recommended | none received |
Who spoke
Snowdome Foundation · Lymphoma Australia · Rare Cancers Australia
What the PBS pays
$3M in government benefit over 2024–25, across 1,006 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pralatrexate | $3.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.